Rationale: A stable 40-kDa fragment is produced from cardiac myosin-binding protein C when the heart is stressed using a stimulus, such as ischemia-reperfusion injury. Elevated levels of the fragment can be detected in the diseased mouse and human heart, but its ability to interfere with normal cardiac function in the intact animal is unexplored.
M yosin-binding protein C (MyBP-C) is a thick-filament-associated protein consisting of 1274 amino acid residues (149 kDa), which is localized to the crossbridgecontaining C zones in the sarcomeres of striated muscles. 1 Three isoforms of MyBP-C, fast skeletal, slow skeletal, and cardiac, are present in humans and mice. 2, 3 Although the 3 isoforms have similarities, the cardiac isoform of MyBP-C (cMyBP-C) differs from the skeletal isoforms in that it contains an additional domain at the N-terminus (C0) and a phosphorylatable domain located between the C1 and C2 domains ( Figure 1B ). The ATPase-binding regions of the actin and myosin heavy chains lie at the amino terminus of the protein. 4 The importance of understanding the structure-function relationships of cMyBP-C is underscored by the identification of numerous MYBPC3 mutations that are responsible for an estimated 20% to 35% of verified familial hypertrophic cardiomyopathy (FHC) cases. 5, 6 Although mutation of MYBPC3 is one of the most frequent causes of hypertrophic cardiomyopathy on a per-gene basis, most of these mutations (≈60%) result not in a full-length mutated protein, but rather in truncated peptides. We recently confirmed that cardiac stress can trigger the production and accumulation of a 40-kDa truncated fragment derived from the amino terminus of cMyBP-C. The fragment seems to be generated as a result of dephosphorylation that unmasks a μ-calpain site, resulting in cleavage of intact cMyBP-C. 7 A recent report using neonatal rat ventricular cardiomyocytes showed that hypoxic stress resulted in decreased levels of cMyBP-C phosphorylation, its specific cleavage, and the subsequent production of N′-terminal fragments. 8 The 40-kDa fragment can be detected in diseased and stressed mouse and human hearts. [7] [8] [9] The fragment is apparently stable; however, the functional consequences in terms of normal cardiac function are unknown. Appreciable quantities of a truncated fragment of cMyBP-C in the diseased human heart raises the possibility of potential pathogenic consequences because the fragment has been shown to effectively compete for the normal protein's sites of binding to the head regions of myosin and actin. 10 Considering the frequency with which truncated cMyBP-C protein can serve as a poison peptide, 2 we sought to determine the potential pathogenicity of the 40-kDa fragment in vivo. We generated cardiac myocyte-specific transgenic mice using a Tet-Off inducible system to permit controlled expression in cardiomyocytes. 11 When the expression of the 40-kDa protein is induced in the hearts by crossing the responder animals with tetracycline transactivator (tTA) mice (double-transgenic [DTG] ) in the absence of doxycycline, the DTG mice undergo sarcomere dysgenesis, show altered cardiac geometry, and display signs of heart failure by 3 weeks of age, even though intact cMyBP-C expression is unaffected. Expression of the 40-kDa fragment in cardiomyocytes led to development of significant cardiac hypertrophy with myofibrillar disarray and fibrosis. Because hypertrophy seemed to be directly caused by this fragment's expression, we wished to determine whether normal pathogenic signaling was activated or whether some novel pathway was involved. Mitogen-activated protein kinase is one of the major signaling pathways involved in cardiac hypertrophy and heart failure, and we subsequently explored the role of this pathway in the developing pathology. MEK-ERK hypertrophic signaling pathways were activated in the 40-kDa fragmentbearing mice; treating the animals with intraperitoneal injections of U0126, a MEK-ERK pathway inhibitor, effectively improved cardiac function and prolonged survival compared with the untreated control mice.
Methods

DNA Constructs and Transgenic Mice
For cardiomyocyte-specific inducible transgene expression, 2 lines of mice are needed. The driver line (tTA) contains the α-myosin heavy chain promoter fused to tet-VP16 protein, which has been described previously. 12 We generated the responder line containing the myosin heavy chain promoter driving the 40-kDa N-terminal fragment of cMyBP-C (amino acids, 1-271). 7, 13, 14 An N-terminal c-myc tag encoding the human c-myc peptide (EQKLISEEDL), which has no effect on cMyBP-C function and stability, was inserted after the , diseased, nonischemic (NI), and ischemic (I) samples. B, cMyBP-C structure and transgenic (TG) constructs. cMyBP-C is a 149-kDa protein comprising 8 immunoglobulin-type (ovals) and 3 fibronectin-like (octagon) domains. The protein binds multiple components of the thick and thin filaments and the location of the 40-kDa fragment is shown. One mouse line contains the cardiomyocyte-specific promoter driving the fusion tet-VP16 protein (tetracycline transactivator [tTA] ) that, in the absence of tetracycline, will bind to the responder promoter and drive expression of the 40-kDa fragment. We generated multiple lines of cardiomyocyte-specific TG mice, choosing a line that showed reasonably tight control of the transgene and producing levels that approximated those in human disease. B and C, 
Protein Analyses
To identify modifications at the protein level, enriched myofibrillar proteins were isolated using F60 buffer (60 mmol/L KCl; 30 mmol/L imidazole; 7.2 mmol/L MgCl 2 ; pH 7.0) with protease/phosphatase inhibitors (Cocktails I and II; Sigma), as described previously. 15 The presence of the 40-kDa protein was confirmed by SDS-PAGE (12.5% criterion Tris-glycine precast gels; Bio-Rad), followed by Western blots using an anti-c-myc monoclonal antibody (clone 9E10; Roche) and an anti-cMyBP-C rabbit polyclonal antibody raised against the C0-C1 domains.
16,17
Evaluation of cMyBP-C Phosphorylation
To define cMyBP-C phosphorylation status, myofibrillar proteins were purified from nontransgenic and 40-kDa single-transgenic and DTG mouse hearts, electrophoresed by SDS-PAGE, and subjected to Western blotting using phospho-specific cMyBP-C antibodies, as described previously. 18 
Histochemistry, Immunohistochemistry, and Transmission Electron Microscopy
For histopathologic examinations, beating hearts were removed from anesthetized mice, the blood was allowed to drain, and the tissues were fixed in 10% formalin. Hearts were bisected longitudinally, dehydrated through a graded series of alcohol, and laid open before being embedded in paraffin.
Step-serial sections (5 μm) were taken from 2 to 3 hearts per group. Sections were stained with Masson trichrome. Fibrosis, myocyte disarray, and calcification were each evaluated by an expert pathologist who was blinded to genotype. Localization and integration of the 40-kDa cMyBP-C fragment in the sarcomeres were determined by immunohistochemistry with confocal microscopy, as described previously. 18 Ultrastructural analyses were performed by electron microscopy as described previously. 14, 19 Briefly, mice were anesthetized with isofluorane and the hearts were fixed by perfusion with 1% paraformaldehyde and 2% glutaraldehyde in cardioplegic buffer (5% dextrose; 30 mmol/L KCl in phosphate-buffered saline) for 2 minutes, followed by treatment with fixative in 100 mmol/L cacodylate buffer (pH 7.3). The hearts were then excised and subsequently separated into the left ventricle and septum. Each region was then divided into small (1 mm) cubes and fixed in glutaraldehyde-cacodylate fixative overnight at 4°C. The tissue fragments were postfixed in 1% OsO 4 in cacodylate buffer, dehydrated in a series of acetone baths, and embedded in a Poly/Bed 812 resin mixture. Thin sections, counterstained with uranium and lead salts, were examined using a Hitachi 7600 transmission electron microscope equipped with an Advanced Microscopy Techniques digital camera. Multiple sections were cut from 2 to 3 mice of mixed sexes, and >50 fields were observed by a blinded observer.
Cardiac Function
To observe changes in left ventricular chamber size and fractional shortening, echocardiography was performed by noninvasive M-mode echocardiography.
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MEK Inhibitor Treatment
Mice were treated with U0126, a pharmacological inhibitor of mitogen-activated protein kinase/ERK, which blocks phosphorylation of ERK1/2. 20 We injected U0126 intraperitoneally on a daily basis (5 mg/kg body weight per day) into pregnant dams until delivery and continued the injections during the perinatal and neonatal periods to the nursing females up to postnatal day 9 and then to individual pups until postnatal day 24 at 2-day intervals. After weaning, individual mice were treated until ≤12 weeks of age.
Statistical Analyses
All biochemical and functional assays were performed in mice with mixed-sex controls. For comparisons of data from 2 groups, Student t test was used. For comparisons of multiple groups, 1-way ANOVA with post hoc Tukey multiple comparisons test was used. Paired data were evaluated by Student t test. Results are shown as mean ± SE or SD. A value of P < 0.05 was considered significant.
Results
Inducible Cardiomyocyte-Specific Expression of the 40-kDa Fragment
Previously, we found that cleavage of cMyBP-C by μ-calpain produced a stable 40-kDa fragment. This fragment, which was either undetectable or present in very small amounts in normal mouse hearts, was easily detectable in both mouse and human hearts that had been subjected to ischemia-reperfusion injury or general cardiovascular stress. 7 Using isolated systems, we found that this fragment was able to interact efficiently with the other filament systems in the sarcomere and, in fact, could compete effectively with endogenous cMyBP-C for binding to the thick and thin filaments. 10, 21 On the basis of these data and the presence of cMyBP-C in hearts collected from human heart failure patients, we wanted to determine whether production of the 40-kDa fragment was merely a consequence of cardiac disease or whether its expression was sufficient to cause cardiac pathology and dysfunction. It was therefore imperative to be able to rigorously control expression of the 40-kDa fragment independent of exogenously induced cardiac stress. We therefore chose to express the 40-kDa fragment inducibly using a Tet-Off system.
Before initiating the transgenic studies, we confirmed the levels of the 40-kDa fragment in normal and failing human hearts to titrate transgenically driven expression to the approximate levels observed in our human samples. Although low levels could be detected in our nonfailing samples, the amount of 40-kDa fragment seen in hearts with either ischemic or nonischemic disease was substantially increased ( Figure 1A) . To investigate the role of the 40-kDa fragment of cMyBP-C in cardiac function and its intrinsic ability to cause cardiac disease, we generated cardiac-specific transgenic mice using our inducible transgenic system, which is bigenic and consists of 1 line (the driver) producing the tTA, under the control of the α-myosin heavy chain promoter, and another line carrying the cDNA encoding the 40-kDa fragment, under the control of the responder promoter, which is only active in the absence of doxycycline ( Figure 1B) . 22 The amino terminus of cMyBP-C binds multiple components of the thick and thin filaments, interacting with actin and myosin, and the 40-kDa fragment contains elements of both these binding sites, as schematically shown in Figure 1B . When these 2 transgenic lines were crossed and in the absence of tetracycline/doxycycline, the 40-kDa fragment was expressed specifically in cardiomyocytes ( Figure 1C) . The fragment's synthesis had no visible effect on normal protein synthesis patterns ( Figure 1C) , and normal levels of the intact wild-type cMyBP-C protein seemed to be present.
We had previously shown that cMyBP-C function is highly dependent on its phosphorylation state. 7, 9, 13, 18 To determine whether expression of the 40-kDa fragment had any effect on the overall phosphorylation status of intact cMyBP-C, we performed Western blotting analyses with phospho-site-specific antibodies that we had developed and used previously, which are able to detect the phosphorylation status of 3 specific residues-serines 272, 282, and 302 in the amino terminus of cMyBP-C. 18 No significant changes in phosphorylation were observed in any of the mice, ruling out posttranslational modulation of the endogeneous protein as playing a role in any functional deficits that might be observed ( Figure 1D ).
Cardiac Phenotype and Sarcomere Architecture
The mice began displaying overt signs of cardiac dysfunction in early adulthood. Removal of hearts from nontransgenic, single-transgenic, and induced DTG mice at 12 weeks revealed grossly aberrant cardiac morphology in hearts expressing the 40-kDa fragment (Figure 2 ). Chamber arrangement and overall geometries were grossly perturbed, with apparent ventricular and atrial enlargement.
To determine whether the 40-kDa fragment is incorporated normally into the sarcomere, we isolated the myofibrillar proteins from nontransgenic and the 40-kDa fragment-bearing single-transgenic and DTG mice. Western blotting was performed with cMyBP-C N-terminal antibody, which detects both the full-length protein and the 40-kDa fragment ( Figure 3A) . Quantification showed no significant changes in the levels of full-length MyBP-C expression among nontransgenic 40-kDa fragment-bearing single-transgenic, tTA, and DTG mice ( Figure 3B ). Significantly higher (P < 0.0001) levels of the 40-kDa fragment were detected only in myofibril protein preparations from DTG hearts ( Figure 3C ), suggesting that the 40-kDa fragment was incorporated into the sarcomere. Some leakage was observed in expression of the 40-kDa fragment in the single-transgenic mice carrying that construct ( Figure 1B ; 40 kDa). To confirm localization of the 40-kDa fragment, antibodies against cMyBP-C and c-myc were used for immunohistochemistry coupled with confocal microscopy. Results showed that the 40-kDa fragment colocalized with cMyBP-C in the DTG hearts, indicating that the fragment was incorporated in a manner indistinguishable from normal endogeneous cMyBP-C at the resolution used ( Figure 3D ).
Myocardial fibrosis, a hallmark of FHC, 23 can contribute to sudden cardiac death, ventricular tachyarrhythmia, left ventricular dysfunction, and heart failure. 24 We assessed fibrosis at 4, 12, and 16 weeks ( Figure 4A , 4B, and 4C, respectively). Fibrosis was seen as early as at 4 weeks in the DTG mice that expressed the 40-kDa fragment and progressively increased as the animals aged, with no fibrosis observed in the nontransgenic and the 40-kDa-bearing and tTA transgenic mice (Figure 4 ). The ratio of heart weight to body weight also was significantly increased (P<0.0001) in the DTG mice compared with that in nontransgenic, 40-kDa-bearing, and tTA transgenic mice ( Figure 4D ). These anatomical and histological alterations were accompanied by visible changes at the ultrastructural level as well. Disorganized sarcomeres are commonly observed in cMyBP-C-related FHC 19 ; thus, we examined the DTG myocardial ultrastructure at 12 weeks. In the unaffected animals, the sarcomeres were aligned with one another, precisely aligned, and the mitochondria were highly organized ( Figure 5 ). In contrast, sarcomeres derived from the 40-kDa DTG mice were consistently out of register, normal pattern organization was significantly disrupted, and the overall architecture of the mitochondria was severely disrupted ( Figure 5 ). Thus, expression of the 40-kDa fragment, even in the presence of wild-type levels of normal protein ( Figure 3B ), resulted in overt cardiac pathology and sarcomeric disruption, indicating that this fragment can act in a dominant-negative poison-peptide fashion and directly result in cardiac pathology in the context of the whole animal.
MEK-ERK Pathways Are Activated in Hearts Expressing the 40-kDa Fragment
Enhanced MEK and ERK activation in cardiomyocytes is strongly implicated in the pathogenesis of FHC. 25 Therefore, we wished to determine whether the 40-kDa fragmentinduced pathogenesis resulted in activation of these pathways as well. On phosphorylation, MEK becomes activated and subsequently signals downstream to ERK, eventually resulting in specific transcriptional programs being upregulated. 26, 27 Hearts were isolated from 5-and 10-week-old mice and the phosphorylation status of MEK and ERK was determined by Western blot analysis using phospho-specific antibodies. MEK-ERK pathways are highly activated in the 40-kDa DTG mice compared with nontransgenic and 40-kDa-bearing single-transgenic mice. Moreover, DTG mice displaying obvious signs of heart failure (anasarca, fluid retention, and listlessness) showed the highest levels of MEK-ERK activation ( Figure 6 ).
We hypothesized that aspects of the pathogenic phenotype being observed were because of upregulation of this pathway. Pathogenicity therefore might be ameliorated by MEK-ERK inhibition. We treated the 40-kDa DTG mice with the MEK inhibitor U0126. The untreated 40-kDa DTG mice began to die as early as 23 days after birth, with a majority of the mice deceased by 8 weeks. In contrast, only 1 MEK inhibitor-treated animal died within 8 weeks and there were significant increases in lifespan and probability of survival relative to the untreated cohort ( Figure 7A ).
After 12 weeks, cardiac function was measured by M-mode echocardiography. Fractional shortening in the untreated DTG mice was significantly decreased compared with the nontransgenic, 40-kDa-bearing, and tTA mice (P<0.0001). However, the U0126-treated cohort showed significantly higher values (P<0.01) relative to the untreated induced DTG mice ( Figure 7B ). Left ventricular mass and conservation of normal diastolic volumes were also significantly improved (P<0.0001; Figure 7C and 7D) . These results suggest that activation of the MEK-ERK pathway plays a significant role in early mortality but clearly, although mitogen-activated protein kinase inhibition can improve overall cardiac function, it cannot rescue the animal in the face of continued production of the 40-kDa fragment.
Discussion
This report significantly extends earlier data concerning the origin and function of an endogeneously produced peptide fragment derived from cMyBP-C. The 40-kDa fragment, derived from the N-terminus of cMyBP-C, contains the C0 domain (99 residues), a Pro/Ala-rich region (51 residues), the C1 domain (104 residues), and 17 residues of the M domain ( Figure 1B) . Previously, we found that the 40-kDa fragment is released via cleavage at a μ-calpain site and that steadystate levels were increased after cardiac stress, such as surgically induced pressure overload or ischemia-reperfusion injury. We also found high levels of the fragment in a number of our genetically induced models of cardiac disease (data not shown) and, recently, the fragment was detected in the circulatory systems of rodents and humans after acute myocardial infarction. 7, 8 A recent report showed that the presence of the 40-kDa fragment correlated with increased cytotoxicity, impairment of Ca 2+ handling, and altered contractile function of the sarcomere in vitro, whereas, in contrast, a fragment derived from the carboxyl terminus of cMyBP-C had no detrimental effects. 28 In this article, we detail for the first time the results of dosage-controlled expression in vivo in the cell type in which the fragment accumulates in human disease. We show that at high doses, the fragment is sufficient to cause cardiac disease, heart failure, and premature death. Significantly, in some human heart failure patients, we can detect significant levels of the fragment in both ischemic and nonischemic conditions ( Figure 1A ), raising the possibility that the 40-kDa fragment may play a role in the natural history of human cardiac disease.
Under normal conditions in the mouse, in our experience, only ≈80% of the cMyBP-C is fully phosphorylated, holding the possibility that low levels of the fragment might accumulate at baseline with no detectable ill effects. This appears to be the case in humans as well; the nondiseased samples contain detectable amounts of the fragment ( Figure 1A) . Consistent with these data is the observation that in our mouse model in which transgene expression is not induced but in which there is a slight amount of leaky expression ( Figure 3A) , we detected no pathology. The data are consistent with a dose-dependent pathogenic effect of the fragment, which comes about as a consequence of its ability to interfere with the interactions of normal cMyBP-C with thick and thin filaments. 10 Consistent with the fragment's specificity for causing the observed pathogenic effects, when we turned off expression of the 40-kDa fragment by administering doxycycline postbirth, we did not see any heart enlargement or sign of heart failure in those animals (data not shown).
Considering our data and the particularly elevated levels of the 40-kDa fragment in cardiac samples derived from patients with heart failure, we thought it would be important to determine its potential pathogenicity. Is the 40-kDa fragment sufficient to cause cardiac disease or even failure when expressed in a cardiomyocyte-specific fashion in vivo? When very low levels of the 40-kDa fragment were expressed (ie, when the transgene was present but uninduced, no pathology was presented). However, on induction of expression of the 40-kDa transgene to levels approaching those detected in stressed hearts ( Figure 1A) , we observed sarcomere dysgenesis, altered cardiac geometry, and cardiac failure between 3 and 17 weeks after birth. The mice also had development of significant cardiac hypertrophy, with myofibrillar disarray and fibrosis. These symptoms developed despite the presence of normal amounts of intact cMyBP-C protein, indicating that, in vivo, accumulation of the 40-kDa fragment results in a dominant pathogenic effect. These data are consistent with more recent studies performed in vitro by Sadayappan et al. 28 In those studies using rabbit cardiomyocytes and adenovirus infection, the pathogenic properties of the 40-kDa fragment in vitro were confirmed, whereas fragments derived from other portions of cMyBP-C stably expressed in rabbit cardiomyocytes were benign.
We next addressed the question of mechanism: where is this dominant effect concentrated? The N-terminal 40-kDa region of the cMyBP-C is highly conserved across species 29 and its generation is pathogenic in mammalian hearts. Reductionist approaches have confirmed its ability to affect crossbridge kinetics and effectively compete with intact cMyBP-C for actin and myosin binding; 10, 21 these results are consistent with our data demonstrating its correct placement in the sarcomere (Figure 3) . Bacterially expressed 40-kDa fragment effectively inhibited actin translocation over a surface of monomeric mouse cardiac myosin in an in vitro motility assay. 21 The 40-kDa fragment also stereospecifically and reversibly bound to actin, 10, 30 effectively serving as a brake or drag to slow myosin kinetics. 10 However, we have not ruled out the possibility that the 40-kDa fragment might affect thick and thin filament kinetics by also binding directly to myosin. [31] [32] [33] The direct effect of the fragment's placement on sarcomere function is supported by the effect on structure ( Figure 5 ) where altered sarcomeric architecture is readily apparent. Expression of the fragment had no effects on the steady-state levels of full-length cMyBP-C, implying that the 40-kDa fragment exerts its effect in a dominant fashion, consistent with a proposed pathogenic role in general cardiac disease, even when cMyBP-C levels are unaffected. All of the histological and functional data are consistent with the hypothesis that the pathogenesis of the 40-kDa fragment stems directly from its intercalation into the sarcomere and interference with normal thick and thin filament movement and kinetics. This results in altered cardiac output, cardiomyocyte remodeling and dropout, and subsequent fibrosis, all of which are observed in the 40-kDa fragment model. At this point, we believe that the observed downstream effects have their primary source in altered filament mechanics. Currently, we have neither data nor evidence that the fragment can effectively signal outside of the sarcomere in terms of its ability to activate/inhibit other protective or pathogenic mechanisms.
Enhanced MEK and ERK activation in cardiomyocytes often accompanies development of cardiac pathology in FHC, 25 but there is a paucity of data with reference to altered MEK-ERK pathway contribution to cMyBP-C-related pathology. In the 40-kDa fragment-bearing mice, we detected significant activation of this pathway ( Figure 5 ). Because depletion of ERK1/2 with antisense oligonucleotides or pharmacological inhibition of MEK1/2 attenuates the hypertrophic response to agonist stimulation in cultured cardiomyocytes, 34, 35 we asked whether downregulation of the pathway's activity might be sufficient to ameliorate overall pathology and even prolong life. Treatment with the MEK inhibitor U0126 significantly increased lifespan and substantially improved heart function ( Figure 7 ). These data provide evidence for a critical role of the MEK-ERK pathway in augmenting the development of cardiac disease in the 40-kDa fragment-bearing mice, although they clearly do not rule out the role of other pathways in the pathogenesis of the disease resulting from sarcomeric dysfunction. We hypothesize that with continued alterations of cardiac hemodynamics, multiple signaling pathways that contribute to the overall pathogenicity of the secondary response are altered. In this study, the MEK inhibitor was administered during the perinatal and neonatal periods, before any detectable structural or functional cardiac abnormalities. A critical question to be addressed is whether the MEK inhibitor would be effective in improving heart function in 40-kDa fragmentbearing mice when initiated after the onset of cardiac disease, which would be more analogous to the potential for affecting the natural history of the disease in patient populations.
Although this study shows that relatively high levels of the 40-kDa fragment are sufficient to cause cardiac failure and death, its role in the natural history of cMyBP-C-induced human cardiomyopathy and cardiac disease is not yet defined. Clearly, in some human hearts in which the fragment is present, the levels of intact cMyBP-C are dramatically decreased ( Figure 1A ; ischemic hearts) and cMyBP-C haploinsufficiency could, by itself, cause increased pathology. At the same time, in the nonischemic hearts shown in Figure 1A , although the cMyBP-C levels are somewhat reduced, there are still appreciable amounts. In mouse hearts, expression of the 40-kDa fragment with normal amounts of cMyBP-C still causes disease and premature death, leading us to hypothesize that, in humans, appreciable amounts of this fragment will negatively affect the natural history of preexisting cardiac disease.
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